AG真人官方

Calgary, Alberta--(Newsfile Corp. - September 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, celebrated the 17+ years of life gained by Howie Lindeman, the results of Howie's VesCell™ treatment in 2008.

Florida's law now authorizes the use of VesCell™ in patients with life-threatening or debilitating conditions who have exhausted standard-of-care treatment options. To explain the 17 years he gained from one VesCell™ treatment for ischemic cardiomyopathy, Howie Lindeman, a six-time Grammy Award-winning producer and recording engineer, shared his experience as one of VesCell's™ longest-living recipients ().

Cannot view this video? Visit:

A Family History and a Life-Changing Decision

At the age of 39, Howie suffered his first heart attack, marking the beginning of his battle with severe heart disease. As patient treated in 2008, Howie's journey offers a helpful testament to those individuals who have no-option cardiovascular disease.

Howie's heart condition was not unexpected, given his family history. Both his father and grandfather succumbed to coronary artery disease. Facing the prospect of open-heart surgery, Howie sought alternatives to the invasive procedure. His research led him to VesCell™, an innovative therapy using a patient's own blood-derived stem cells to restore circulation and improve cardiac function. "I was determined to find another way," Howie shared in his testimonial, reflecting on his decision to pursue VesCell™ over traditional surgery. His choice was informed by a review of clinical data and the therapy's potential to address his ischemic cardiomyopathy as an alternative to open heart surgery.

Life Before and After VesCell™

Before treatment, Howie described his quality of life as severely diminished, a common experience for those with advanced heart disease. "I thought my life as I knew it was over," he recalled, noting the fatigue and limitations imposed by his condition. After receiving VesCell™ (ACP-01), Howie experienced a dramatic improvement. His ejection fraction, (volume of blood ejected with each heart beat) nearly doubled, from the low 20% range to the 40% range, as noted in his interview. "This therapy gave me my life back," Howie said. "I feel stronger, healthier, and more hopeful than I ever thought possible."

Lessons Learned and a Message of Hope

Howie's experience underscores the potential of stem cell therapy to improve ejection fraction and survival in heart failure patients. A 2025 peer-reviewed article in highlights how VesCell™ (ACP-01) fosters angiogenesis and reduces inflammation, offering a scientific foundation for its benefits.

Howie's story also emphasizes the importance of exploring innovative treatments when standard options fall short. "I learned to never give up hope and to seek out solutions that align with your body's natural healing potential." he shared.

Hemostemix's VesCell™ has treated 498 patients across seven clinical studies, with results published in 11 peer-reviewed publications. In peer reviewed published studies ( and ), the therapy has shown up to a 47.1% increase in ejection fraction in dilated cardiomyopathy patients.

"Stories like Howie's are our drum beat. They inspire us to make VesCell™ widely available to patients who have no other options," said Thomas Smeenk, CEO.

For more information or to book a consultation, visit . To hear Howie Lindeman's full story, watch his testimonial at ().

Cannot view this video? Visit:

ABOUT HEMOSTEMIX

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell™ (ACP-01). A recent peer-reviewed article in provides the scientific foundation for how ACP-01 and NCP-01 may enhance brain-computer interface performance by reducing inflammation, fostering angiogenesis and synaptic plasticity, and potentially extending implant longevity. Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for , , , , , and . Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the . As compared to a five year mortality rate of 50% in the CLTI patient population, reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit .

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to the Company's boots on the ground sales strategy in furtherance of the financing of sales of VesCell™ (ACP-01), and the commercialization of ACP-01 via the sale and financing of compassionate treatments under Florida SB 1768. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at . Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

To view the source version of this press release, please visit